The U.S. biopharmaceutical industry has seen remarkable growth since the 2017 Tax Cuts and Jobs Act (TCJA) took effect. More than $160 billion has been invested in domestic facilities, over 4 million jobs are now supported, and corporate inversions—once a major threat to U.S. competitiveness—have dropped to zero.